Agenda Now Available Online

NEW YORK, NY – August 21, 2015 – The Cardiovascular Research Foundation (CRF) has announced the late-breaking trials and first report investigations that will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) 2015 scientific symposium. From an unprecedented number of high-quality submissions, TCT has chosen 20 studies that will impact the care of patients and how physicians think about cardiovascular disease. TCT, the world’s premier educational meeting specializing in interventional cardiovascular medicine, will take place October 11-15, 2015 at the Moscone Center in San Francisco, California.

Every year, TCT features major medical research breakthroughs and highlights the latest data on the most innovative treatments that are currently or soon to be available to patients. The studies selected will examine the effectiveness and safety of minimally invasive techniques, pharmaceuticals, technologies, and devices that show potential to treat or prevent cardiovascular disease, the leading cause of death in the world. Late-breaking clinical trials and first report investigations will be presented in the Main Arena and highlighted during press conferences scheduled for Monday, October 12; Tuesday, October 13; Wednesday, October 14; and Thursday, October 15.

The complete agenda for TCT 2015 is also available online. Browse through a wide array of topics and learn more about individual sessions, presentations, and faculty on the TCT Web site. Media are invited to attend TCT; press credentials and registration information can be found here: http://www.crf.org/tct/press/press-credentials-and-guidelines.

Monday, October 12

  • ABSORB III: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease -Dean J. Kereiakes
  • ABSORB China: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease -Run-Lin Gao
  • A Prospective Randomized Trial of Transradial vs Transfemoral Access in Patients Undergoing Coronary Angiography and Intervention -Shigeru Saito
  • ABSORB II: A Prospective Randomized Trial of an Everolimus-Eluting Bioresorbable Scaffold vs an Everolimus-Eluting Metallic Stent in Patients With Coronary Artery Disease – Two-Year Outcomes -Bernard R. Chevalier
  • BIOSOLVE II: Evaluation of a Sirolimus-Eluting Bioresorbable Metallic Scaffold – Six-Month Clinical, Angiographic, and Imaging Outcomes -Michael Haude

Tuesday, October 13

  • RIVER-PCI: A Prospective, Double-blind, Placebo-Controlled Randomized Trial of Ranolazine in Patients With Incomplete Revascularization After Coronary Intervention -Giora Weisz
  • EXPLORE: A Prospective Randomized Trial of Chronic Total Occlusion Intervention Versus Medical Therapy After Successful Primary Angioplasty in Patients With ST-Segment Elevation Myocardial Infarction -Jose P.S. Henriques
  • TOTAL: A Prospective Randomized Trial of Thrombus Aspiration in Patients With ST-Segment Elevation Myocardial Infarction – One-Year Outcomes -Sanjit S. Jolly
  • A Prospective Randomized Trial of Thrombus Aspiration in Patients With ST-Segment Elevation Myocardial Infarction Presenting Late After Symptom Onset -Steffen Desch
  • PLATFORM: Quality-of-Life and Economic Outcomes of an FFR-CT Diagnostic Strategy in Patients With Suspected Coronary Artery Disease -Mark Andrew Hlatky

Wednesday, October 14

  • LEADERS FREE: A Prospective, Double-blind Randomized Trial of a Polymer-Free Biolimus-Eluting Stent Versus Bare Metal Stents in Patients With Coronary Artery Disease at High Risk for Bleeding -Philip M. Urban
  • TUXEDO: A Prospective Randomized Trial of Paclitaxel-Eluting vs Everolimus-Eluting Stents in Diabetic Patients With Coronary Artery Disease -Upendra Kaul
  • PANDA III: A Prospective Randomized Trial of 2 Sirolimus-Eluting Bioresorbable-Polymer–Based Metallic Stents With Varying Elution and Absorption Kinetics -Xu Bo
  • ISAR-DESIRE 4: A Prospective Randomized Trial of Plaque Modification With a Scoring Balloon During Drug-Coated Balloon Treatment of Coronary In-Stent Restenosis -Robert A. Byrne
  • IN.PACT SFA: A Prospective Randomized Trial of a Drug-Coated Balloon for Femoropopliteal Lesions – Two-Year Outcomes -John R. Laird Jr

Thursday, October 15

  • BRAVO 3: A Prospective Randomized Trial of Bivalirudin Versus Heparin in Patients Undergoing Transcatheter Aortic Valve Replacement -Thierry Lefevre
  • SAPIEN 3: Evaluation of a Balloon-Expandable Transcatheter Aortic Valve in High-Risk and Inoperable Patients With Aortic Stenosis – One-Year Outcomes -Howard C. Herrmann
  • RESPECT: A Prospective Randomized Trial of PFO Closure In Patients With Cryptogenic Stroke - Long-Term Results -John D. Carroll
  • Evaluation of Initial Surgical Versus Conservative Strategies in Patients With Asymptomatic Severe Aortic Stenosis -Tomohiko Taniguchi
  • PARTNER II Valve-in-Valve Registry: Evaluation of a Balloon-Expandable Transcatheter Aortic Valve in Patients With Failed Bioprosthetic Surgical Aortic Valves -John G. Webb

Receive updates on Twitter: http://twitter.com/TCTConference.

Press Contacts

Irma Damhuis
Director, External Relations
Tel: 646-434-4690

Judy Romero
Program Manager, External Relations
Tel: 646-434-4608

Eucomed Guidelines go into effect
1 January 2018, update your TCTMD profile to be eligible for Grant Support to attend CRF meetings including TCT! https://www.tctmd.com/